Hospitalization as an outcome in ambulatory COVID-19 trials-not applicable in every setting.
作者信息
Núñez Isaac, Valdés-Ferrer Sergio Iván, Soto-Mota Adrian
机构信息
Department of Medical Education, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Department of Neurology & Psichiatry, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
出版信息
Clin Microbiol Infect. 2022 Sep;28(9):1187-1188. doi: 10.1016/j.cmi.2022.05.026. Epub 2022 May 30.
Abstract
摘要
相似文献
1
Hospitalization as an outcome in ambulatory COVID-19 trials-not applicable in every setting.住院作为门诊COVID-19试验的一个结果——并非在每种情况下都适用。
Clin Microbiol Infect. 2022 Sep;28(9):1187-1188. doi: 10.1016/j.cmi.2022.05.026. Epub 2022 May 30.
2
Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.莫努匹拉韦和奈玛特韦/利托那韦：新型可用的新冠病毒抗病毒药物选择
Acta Med Indones. 2022 Oct;54(4):638-644.
3
An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19.关于莫努匹韦的使用的最新实用指南，以及与具有治疗 COVID-19 的紧急使用授权的药物的比较。
Diabetes Metab Syndr. 2022 Feb;16(2):102396. doi: 10.1016/j.dsx.2022.102396. Epub 2022 Jan 13.
4
Nirmatrelvir-remdesivir association for non-hospitalized adults with COVID-19, point of view.尼马曲韦-瑞德西韦联合治疗非住院 COVID-19 成人患者：观点。
Inflammopharmacology. 2022 Oct;30(5):1927-1931. doi: 10.1007/s10787-022-01055-2. Epub 2022 Aug 18.
5
A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel.在以色列一家大型三级中心住院的 COVID-19 患者中评估瑞德西韦对病毒载量影响的真实环境评估。
Clin Microbiol Infect. 2021 Jun;27(6):917.e1-917.e4. doi: 10.1016/j.cmi.2021.02.029. Epub 2021 Mar 9.
6
COVID-19 updates: Remdesivir (Veklury) in high-risk outpatients with COVID-19.2019冠状病毒病最新情况：瑞德西韦（Veklury）用于高危2019冠状病毒病门诊患者。
Med Lett Drugs Ther. 2022 Feb 21;64(1644):31-32.
7
Treatment Options for Patients With Mild-to-Moderate Coronavirus Disease 2019 in Korea.韩国轻度至中度 2019 冠状病毒病患者的治疗选择。
J Korean Med Sci. 2022 Dec 12;37(48):e352. doi: 10.3346/jkms.2022.37.e352.
8
PF-07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID-19 patients.PF-07321332（奈玛特韦）与人类 ENT1 或 ENT2 不相互作用：对 COVID-19 患者的影响。
Clin Transl Sci. 2022 Jul;15(7):1599-1605. doi: 10.1111/cts.13292. Epub 2022 May 16.
9
Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug?我们用瑞德西韦（一种老药新包装）找到了治疗新冠病毒肺炎的万灵药了吗？
J R Coll Physicians Edinb. 2020 Jun;50(2):159-161. doi: 10.4997/JRCPE.2020.217.
10
Arguments in favour of remdesivir for treating SARS-CoV-2 infections.支持瑞德西韦治疗新型冠状病毒感染的论据。
Int J Antimicrob Agents. 2020 Apr;55(4):105933. doi: 10.1016/j.ijantimicag.2020.105933. Epub 2020 Mar 6.
引用本文的文献
1
Pyridostigmine reduces mortality of patients with severe SARS-CoV-2 infection: A phase 2/3 randomized controlled trial.溴吡斯的明可降低重症 SARS-CoV-2 感染患者的死亡率：一项 2/3 期随机对照试验。
Mol Med. 2022 Nov 8;28(1):131. doi: 10.1186/s10020-022-00553-x.
本文引用的文献
1
Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2.抗病毒药物对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎亚型BA.2的疗效
N Engl J Med. 2022 Apr 14;386(15):1475-1477. doi: 10.1056/NEJMc2201933. Epub 2022 Mar 9.
2
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.奈玛特韦片/利托那韦片组合包装口服药用于伴有进展为重症高风险因素的 COVID-19 门诊患者。
N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
3
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.瑞德西韦早期治疗可降低门诊患者重症 COVID-19 进展风险
N Engl J Med. 2022 Jan 27;386(4):305-315. doi: 10.1056/NEJMoa2116846. Epub 2021 Dec 22.
4
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.莫努匹韦片用于非住院 COVID-19 患者的口服治疗。
N Engl J Med. 2022 Feb 10;386(6):509-520. doi: 10.1056/NEJMoa2116044. Epub 2021 Dec 16.
5
Assessing the evidence on remdesivir.评估关于瑞德西韦的证据。
Lancet Infect Dis. 2021 Dec;21(12):1630. doi: 10.1016/S1473-3099(21)00693-9.
6
Methods of Public Health Research - Strengthening Causal Inference from Observational Data.公共卫生研究方法——加强基于观察性数据的因果推断
N Engl J Med. 2021 Oct 7;385(15):1345-1348. doi: 10.1056/NEJMp2113319. Epub 2021 Oct 2.
7
Hospital load and increased COVID-19 related mortality in Israel.以色列的医院负担与新冠病毒相关死亡率上升
Nat Commun. 2021 Mar 26;12(1):1904. doi: 10.1038/s41467-021-22214-z.
8
Humanitarian crises in a global pandemic.全球大流行中的人道主义危机。
Lancet. 2020 Aug 15;396(10249):447. doi: 10.1016/S0140-6736(20)31749-9.
9
A minimal common outcome measure set for COVID-19 clinical research.用于 COVID-19 临床研究的最小通用结局指标集。
Lancet Infect Dis. 2020 Aug;20(8):e192-e197. doi: 10.1016/S1473-3099(20)30483-7. Epub 2020 Jun 12.
10
Pulse Oximetry for Monitoring Patients with COVID-19 at Home. Potential Pitfalls and Practical Guidance.脉氧仪在家中监测 COVID-19 患者：潜在陷阱与实用指南。
Ann Am Thorac Soc. 2020 Sep;17(9):1040-1046. doi: 10.1513/AnnalsATS.202005-418FR.
Zotero 插件